B
Bositao Controlled Release Pharmaceutical Co
A high-tech enterprise with a new drug delivery system as its core
About Bositao Controlled Release Pharmaceutical Co
Bositao Controlled Release Pharmaceutical Co., Ltd., also known as Bostal Drug Delivery, operates as a technology-focused pharmaceutical company specializing in drug delivery systems. Founded in 2013 by Dr. Ron Liu in Guangzhou, China, the company leverages the foundation of Bostal LLC (formerly AustarPharma), which Dr. Liu established in New Jersey, USA, in 2004. Dr. Liu, an expert in pharmaceutical formulation technologies with over 30 years of experience at firms like Pfizer, Abbott, and Bristol-Myers Squibb, leads the company as Chairman and CEO. His background includes authoring "Water-Insoluble Drug Formulation" and serving on the NIH's New Drug Release Technology review committee.
The company's business model is centered on providing a "one-stop" platform for drug development and commercialization for its clients, primarily international pharmaceutical companies. This integrated service encompasses formulation development, pharmacodynamics, toxicology, clinical studies, contract manufacturing, and registration. A significant milestone was the 2009 acquisition of an Abbott Laboratories cGMP commercial manufacturing facility in Edison, New Jersey, which now serves as the corporate headquarters and can produce two billion solid oral dosage units annually. The company has also established a major presence in Guangzhou with a 68,000 square meter International Pharmaceutical Park and passed inspections by both the US FDA and China's NMPA.
Bositao specializes in advanced drug delivery technologies, particularly for controlled-release and water-insoluble drugs. Its technology platforms include oral sustained/controlled release preparations, long-acting injectable microspheres, long-acting implants, osmotic pump systems, and solubilization techniques like hot melt extrusion and spray drying. The company develops and manufactures a range of complex formulations such as multi-layered matrix tablets, pellet-filled capsules, and injectable in-situ gels. Its own R&D pipeline focuses on treatments for major diseases including metabolic disorders, psychiatric conditions, and malignant tumors. Bositao also markets and distributes finished generic and specialty drug products in the U.S. through internal development and strategic partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2023 | $28M | $110M | Guangdong Technology Financial Group · Chuangyu Investment · Yuecai Zhongyin | ↗ |
| SERIES BOther financing | Apr 2022 | $28M | $110M | Chuangyu Investment · Guangzhou Jet Biofiltration · Sanmei Investment · Huatai Zijin Investment | ↗ |
Growth signals
Latest recorded traffic for Bositao Controlled Release Pharmaceutical Co is 1.2K monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bositao Controlled Release Pharmaceutical Co in the Guangzhou ecosystem
The Bositao Controlled Release Pharmaceutical Co office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- CIChuangyu Investment
- GBGuangzhou Jet Biofiltration
- SISanmei Investment
Huatai Zijin Investment
Guangdong Technology Financial Group- YZYuecai Zhongyin
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bositao Controlled Release Pharmaceutical Co on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bositao Controlled Release Pharmaceutical Co’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









